Insmed Inc
NASDAQ:INSM
Insmed Inc
Revenue
Insmed Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Insmed Inc
NASDAQ:INSM
|
Revenue
$305.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
99%
|
CAGR 10-Years
39%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Insmed Inc
Revenue Breakdown
Breakdown by Geography
Insmed Inc
Total Revenue:
305.2m
USD
|
Us:
224.2m
USD
|
Japan:
65.7m
USD
|
Europe And Rest Of World:
15.3m
USD
|
Breakdown by Segments
Insmed Inc
See Also
What is Insmed Inc's Revenue?
Revenue
305.2m
USD
Based on the financial report for Dec 31, 2023, Insmed Inc's Revenue amounts to 305.2m USD.
What is Insmed Inc's Revenue growth rate?
Revenue CAGR 10Y
39%
Over the last year, the Revenue growth was 24%. The average annual Revenue growth rates for Insmed Inc have been 23% over the past three years , 99% over the past five years , and 39% over the past ten years .